| A survey of the FDA's AERS database regarding muscle and tendon adverse events linked to the statin drug class KB Hoffman, C Kraus, M Dimbil, BA Golomb Public Library of Science 7 (8), e42866, 2012 | 160 | 2012 |
| The Weber effect and the United States Food and Drug Administration’s Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010 KB Hoffman, M Dimbil, CB Erdman, NP Tatonetti, BM Overstreet Drug safety 37, 283-294, 2014 | 145 | 2014 |
| Amyloid β protein is internalized selectively by hippocampal field CA1 and causes neurons to accumulate amyloidogenic carboxyterminal fragments of the amyloid precursor protein BA Bahr, KB Hoffman, AJ Yang, US Hess, CG Glabe, G Lynch Journal of Comparative Neurology 397 (1), 139-147, 1998 | 144 | 1998 |
| Analysis of spontaneous postmarket case reports submitted to the FDA regarding thromboembolic adverse events and JAK inhibitors A Verden, M Dimbil, R Kyle, B Overstreet, KB Hoffman Drug safety 41 (4), 357-361, 2018 | 138 | 2018 |
| Stable maintenance of glutamate receptors and other synaptic components in long‐term hippocampal slices BA Bahr, M Kessler, S Rivera, PW Vanderklish, RA Hall, MS Mutneja, ... Hippocampus 5 (5), 425-439, 1995 | 111 | 1995 |
| Induction of β-amyloid-containing polypeptides in hippocampus: Evidence for a concomitant loss of synaptic proteins and interactions with an excitotoxin BA Bahr, B Abai, CM Gall, PW Vanderklish, KB Hoffman, G Lynch Experimental neurology 129 (1), 81-94, 1994 | 93 | 1994 |
| Stimulated reporting: the impact of US food and drug administration-issued alerts on the adverse event reporting system (FAERS) KB Hoffman, AR Demakas, M Dimbil, NP Tatonetti, CB Erdman Drug safety 37, 971-980, 2014 | 70 | 2014 |
| The relationship between adhesion molecules and neuronal plasticity KB Hoffman Cellular and molecular neurobiology 18, 461-475, 1998 | 56 | 1998 |
| Proteolysis of cell adhesion molecules by serine proteases: a role in long term potentiation? KB Hoffman, J Martinez, G Lynch Brain research 811 (1-2), 29-33, 1998 | 55 | 1998 |
| Seizure induced synthesis of fibronectin is rapid and age dependent: implications for long-term potentiation and sprouting KB Hoffman, JK Pinkstaff, CM Gall, G Lynch Brain research 812 (1-2), 209-215, 1998 | 52 | 1998 |
| Activation of NMDA receptors stimulates extracellular proteolysis of cell adhesion molecules in hippocampus KB Hoffman, J Larson, BA Bahr, G Lynch Brain research 811 (1-2), 152-155, 1998 | 45 | 1998 |
| Sialic acid residues indirectly modulate the binding properties of AMPA-type glutamate receptors KB Hoffman, M Kessler, G Lynch Brain research 753 (2), 309-314, 1997 | 39 | 1997 |
| Neuropsychiatric adverse effects of oseltamivir in the FDA Adverse Event Reporting System, 1999-2012 KB Hoffman, A Demakas, CB Erdman, M Dimbil, PM Doraiswamy Bmj 347, 2013 | 38 | 2013 |
| Variants of the receptor/channel clustering molecule gephyrin in brain: distinct distribution patterns, developmental profiles, and proteolytic cleavage by calpain BT Kawasaki, KB Hoffman, RS Yamamoto, BA Bahr Journal of neuroscience research 49 (3), 381-388, 1997 | 37 | 1997 |
| Distinct distributions of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptor subunits and a related 53,000 Mr antigen (GR53) in brain tissue BA Bahr, KB Hoffman, M Kessler, M Hennegriff, GY Park, RS Yamamoto, ... Neuroscience 74 (3), 707-721, 1996 | 36 | 1996 |
| Amyotrophic lateral sclerosis associated with statin use: a disproportionality analysis of the FDA’s adverse event reporting system BA Golomb, A Verden, AK Messner, HJ Koslik, KB Hoffman Drug Safety 41, 403-413, 2018 | 35 | 2018 |
| Delayed and isoform-specific effect of NMDA exposure on neural cell adhesion molecules in hippocampus KB Hoffman, BA Murray, G Lynch, S Munirathinam, BA Bahr Neuroscience research 39 (2), 167-173, 2001 | 30 | 2001 |
| β-Amyloid increases cathepsin D levels in hippocampus KB Hoffman, X Bi, JT Pham, G Lynch Neuroscience letters 250 (2), 75-78, 1998 | 29 | 1998 |
| A pharmacovigilance signaling system based on FDA regulatory action and post-marketing adverse event reports KB Hoffman, M Dimbil, NP Tatonetti, RF Kyle Drug safety 39, 561-575, 2016 | 27 | 2016 |
| Development of a drug safety ePlatform for physicians, pharmacists, and consumers based on post-marketing adverse events KB Hoffman, BM Overstreet, PM Doraiswamy Drugs and Therapy Studies 3 (1), e4-e4, 2013 | 16 | 2013 |
